Your browser is no longer supported. Please, upgrade your browser.
Settings
BLCM Bellicum Pharmaceuticals, Inc. daily Stock Chart
BLCM [NASD]
Bellicum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.99 Insider Own0.60% Shs Outstand33.22M Perf Week-5.83%
Market Cap316.59M Forward P/E- EPS next Y-2.94 Insider Trans-13.06% Shs Float29.18M Perf Month-8.28%
Income-89.80M PEG- EPS next Q-0.70 Inst Own56.60% Short Float15.07% Perf Quarter-7.21%
Sales0.30M P/S1055.29 EPS this Y-39.40% Inst Trans-0.73% Short Ratio9.33 Perf Half Y-3.83%
Book/sh3.11 P/B3.06 EPS next Y0.00% ROA-56.50% Target Price24.29 Perf Year-42.56%
Cash/sh3.40 P/C2.80 EPS next 5Y- ROE-77.20% 52W Range7.41 - 17.00 Perf YTD-30.03%
Dividend- P/FCF- EPS past 5Y- ROI-58.40% 52W High-43.94% Beta-
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low28.61% ATR0.53
Employees110 Current Ratio6.10 Sales Q/Q0.00% Oper. Margin- RSI (14)43.28 Volatility5.86% 5.18%
OptionableYes Debt/Eq0.30 EPS Q/Q-7.50% Profit Margin- Rel Volume0.70 Prev Close9.21
ShortableYes LT Debt/Eq0.23 EarningsNov 08 Payout- Avg Volume471.27K Price9.53
Recom1.40 SMA20-2.60% SMA50-6.86% SMA200-16.07% Volume329,534 Change3.47%
Mar-08-17Initiated Wells Fargo Outperform
Dec-01-16Initiated Raymond James Outperform
Nov-30-16Initiated Ladenburg Thalmann Buy
Nov-02-16Initiated Cantor Fitzgerald Buy $32
Aug-09-16Upgrade Citigroup Neutral → Buy
Feb-25-16Initiated Citigroup Neutral $11
Sep-11-15Upgrade Guggenheim Neutral → Buy
Jul-24-15Initiated Citigroup Buy
Dec-09-17 02:00PM  Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases GlobeNewswire
Nov-08-17 07:00AM  Bellicum Pharmaceuticals to Present at the Jefferies 2017 London Healthcare Conference GlobeNewswire +6.56%
Nov-07-17 04:05PM  Bellicum Reports Third Quarter 2017 Financial Results GlobeNewswire
11:03AM  Is It Time To Buy Bellicum Pharmaceuticals Inc (BLCM)? Simply Wall St.
Nov-01-17 09:17AM  Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T Program at the 59th American Society of Hematology Annual Meeting GlobeNewswire
Oct-24-17 08:13AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : October 24, 2017 Capital Cube
Sep-27-17 06:54AM  Juno Therapeutics Inc (JUNO): 3 Reasons to Be Bullish InvestorPlace
Sep-11-17 10:38AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : September 11, 2017 Capital Cube
Sep-05-17 10:52PM  Bellicum Pharmaceuticals, Inc. Value Analysis (NASDAQ:BLCM) : September 6, 2017 Capital Cube
Sep-01-17 09:49AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : September 1, 2017 Capital Cube
Aug-30-17 07:00AM  Bellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in September GlobeNewswire
Aug-29-17 08:43AM  Bellicum Pharmaceuticals (BLCM) in Focus: Stock Moves 13.8% Higher Zacks +7.22%
Aug-13-17 07:46AM  Edited Transcript of BLCM earnings conference call or presentation 8-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 08:35AM  Houston pharma co. shakes up C-suite again American City Business Journals -9.31%
Aug-08-17 04:05PM  Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
01:10PM  Investor Network: Bellicum Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 07:00AM  Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer GlobeNewswire
Aug-01-17 07:00AM  Bellicum Pharmaceuticals to Report Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8, 2017 GlobeNewswire
Jul-28-17 09:31AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : July 28, 2017 Capital Cube
Jul-24-17 02:24PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : July 24, 2017 Capital Cube
Jul-18-17 08:10AM  5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote Zacks
Jul-16-17 08:03PM  3 Value Stocks for Sharp Investors Motley Fool
Jul-14-17 02:41PM  Can Bellicum Pharmaceuticals Stock Bounce Back? Motley Fool
01:06PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : July 14, 2017 Capital Cube
08:30AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : July 14, 2017 Capital Cube
Jul-03-17 04:11PM  Bellicum Pharmaceuticals, Inc. Value Analysis (NASDAQ:BLCM) : July 3, 2017 Capital Cube
Jun-30-17 09:26AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : June 30, 2017 Capital Cube
Jun-29-17 04:05PM  Here's Why Bellicum Pharmaceuticals Fell as Much as 13.8% Today Motley Fool -9.72%
Jun-28-17 09:29AM  Global Blood Shares Pop on Priority Designation; Kite Pharma Rises on Patent News: Biotech Movers TheStreet.com
Jun-27-17 03:07PM  Analysts Remain Encouraged By Bellicum Pharma's Progress Benzinga
02:59PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : June 27, 2017 Capital Cube
Jun-26-17 11:11AM  Bellicum Pharmaceuticals EHA Presentation Helps Validate Its Platform Benzinga
Jun-23-17 12:14PM  Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout TheStreet.com
07:00AM  Bellicum Reports Clinical Results of BPX-501 in Pediatric Leukemias at the 22nd Congress of the European Hematology Association GlobeNewswire
07:00AM  Bellicum Announces Clinical Data on BPX-501 at Presidential Symposium of the 22nd Congress of the European Hematology Association GlobeNewswire
Jun-22-17 09:36AM  Biotech Movers: Shire, Bellicum, Organovo TheStreet.com +10.51%
Jun-20-17 08:23AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : June 20, 2017 Capital Cube
08:00AM  Today's Research Reports on Stocks to Watch: Rigel Pharmaceuticals and Bellicum Pharmaceuticals Accesswire
Jun-16-17 03:28PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : June 16, 2017 Capital Cube +8.11%
Jun-05-17 02:03PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : June 5, 2017 Capital Cube
Jun-02-17 09:38AM  Bellicum Pharmaceuticals, Inc. :BLCM-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-31-17 07:00AM  Bellicum Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire -6.61%
May-18-17 07:00AM  Bellicum Announces Clinical Presentations at the 22nd Congress of the European Hematology Association GlobeNewswire
May-17-17 04:23PM  3 Growth Stocks You Haven't Thought Of Motley Fool -5.14%
May-16-17 08:45AM  Houston pharmaceutical company announces C-level changes American City Business Journals
May-15-17 04:30PM  Bellicum Pharmaceuticals Announces Management Changes GlobeNewswire
May-11-17 06:17PM  Bellicum Pharmaceuticals, Inc. Value Analysis (NASDAQ:BLCM) : May 11, 2017 Capital Cube
May-09-17 08:52AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : May 9, 2017 Capital Cube
May-08-17 04:05PM  Bellicum Pharmaceuticals Reports First Quarter 2017 Financial Results GlobeNewswire -6.60%
Apr-26-17 07:00AM  Bellicum Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference GlobeNewswire
Apr-21-17 09:34AM  Biotech Movers: XBiotech, Atara, Bellicum TheStreet.com
Apr-11-17 08:15AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : April 11, 2017 Capital Cube
Apr-06-17 04:20PM  The First CAR-T Drugs Have Left the Gate Motley Fool
Apr-05-17 09:23AM  Biotech Movers: Sarepta, Bellicum, Novavax TheStreet.com
Apr-04-17 08:00AM  Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR-T / TCR Technology at AACR GlobeNewswire
Mar-30-17 07:00AM  Bellicum Pharmaceuticals Announces Closing of Public Offering GlobeNewswire
Mar-29-17 08:42AM  Better Buy: Bellicum Pharmaceuticals, Inc. vs. Kite Pharma Motley Fool +5.03%
Mar-27-17 03:51PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : March 27, 2017 Capital Cube
Mar-24-17 04:23PM  BELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -6.67%
08:14AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : March 24, 2017 Capital Cube
Mar-23-17 06:20PM  Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -10.23%
Mar-22-17 04:01PM  Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-20-17 09:26AM  Bellicum Pharmaceuticals, Inc. :BLCM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
Mar-17-17 01:49PM  5 Stocks Trending Close to Major Breakouts
01:04PM  BELLICUM PHARMACEUTICALS, INC Financials
10:27AM  Bellicum Pharmaceuticals, Inc. :BLCM-US: Earnings Analysis: 2016 By the Numbers : March 17, 2017
Mar-13-17 04:07PM  BELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements +6.99%
04:05PM  Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 GlobeNewswire
08:59AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : March 13, 2017
07:07AM  Q4 2016 Bellicum Pharmaceuticals Inc Earnings Release - After Market Close
Mar-08-17 03:53PM  Here's Why Bellicum Pharmaceuticals Went Up as Much as 22% Today at Motley Fool +10.01%
07:00AM  Bellicum Pharmaceuticals to Present at the Barclays Global Healthcare Conference GlobeNewswire
06:06AM  Coverage initiated on Bellicum Pharma by Wells Fargo
Mar-06-17 09:42AM  Better Buy: Bellicum Pharmaceuticals Inc. vs. bluebird bio Inc. at Motley Fool
07:00AM  Bellicum to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call and Webcast on March 13, 2017 GlobeNewswire
Feb-23-17 09:20AM  Biotech Movers: Shire Rises on Encouraging Angioedema Results -5.24%
Feb-22-17 04:15PM  Bellicum Presents Updated Clinical Results at 2017 BMT Tandem Meetings on BPX-501 in Orphan Inherited Blood Disorders and Hematologic Cancers GlobeNewswire
Feb-21-17 07:00AM  Bellicum Announces Initiation of Patient Dosing with Controllable CAR T-Cell Product Candidate GlobeNewswire
Feb-13-17 10:23AM  Moving Average Crossover Alert: Bellicum Pharmaceuticals (BLCM)
Feb-03-17 01:47PM  5 Stocks Setting Up for Big Breakouts +6.75%
Jan-31-17 04:11PM  Houston pharmaceutical company hires new CEO as it prepares for commercialization at bizjournals.com +12.72%
09:21AM  BELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
07:00AM  Bellicum Announces Appointment of Rick Fair as Chief Executive Officer in Preparation for Commercialization of BPX-501 and Next Phase of Growth GlobeNewswire
Jan-06-17 11:26AM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : January 6, 2017
Dec-23-16 01:26PM  5 Stocks Poised for Major Breakouts +7.27%
Dec-21-16 05:23PM  BELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
Dec-19-16 05:06PM  BELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
07:30AM  Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies GlobeNewswire
Dec-14-16 11:38AM  Hedge Funds Arent Crazy About Triple-S Management Corp. (GTS) Anymore at Insider Monkey
Dec-13-16 12:22PM  Better Buy: Ionis Pharmaceuticals, Inc. vs. Bellicum Pharmaceuticals at Motley Fool
Dec-05-16 04:15PM  Bellicum Presents Clinical Results to Date of BPX-501 Pediatric Program and Provides Regulatory Update at Investor Event During ASH Annual Meeting Business Wire
01:00PM  Bellicum Pharmaceuticals Announces GoCAR-T and GoTCR Preclinical Presentations at the American Society of Hematology 2016 Annual Meeting Business Wire
11:52AM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : December 5, 2016
Dec-03-16 12:00PM  Bellicum Announces Updated Clinical Data from BPX-501 Study in Children with Primary Immune Deficiencies and Hemoglobinopathies Business Wire
Nov-29-16 07:26AM  Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : November 29, 2016
Nov-23-16 02:09PM  Why Juno Therapeutics Inc Plummeted Today at Motley Fool
12:44PM  ETFs with exposure to Bellicum Pharmaceuticals, Inc. : November 23, 2016
Nov-21-16 10:44AM  Bellicum Pharmaceuticals, Inc. :BLCM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016
Nov-16-16 04:05PM  Bellicum Pharmaceuticals Recommended for $16.9 Million Award from the Cancer Prevention and Research Institute of Texas Business Wire
Nov-14-16 04:59PM  Biolife Solutions posts record Q3 revenue at bizjournals.com
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company's preclinical product candidates include BPX-601, a GoCAR-T product candidate for treating solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. It has a collaboration agreement with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesu for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Alan K.EVP, Technical OperationsJul 24Sale11.854375,1781,600Jul 26 04:29 PM
Moseley KenSr. VP and General CounselJul 13Option Exercise2.5513,82335,24914,314Jul 17 04:20 PM
Moseley KenSr. VP and General CounselJul 13Sale12.2613,823169,470491Jul 17 04:20 PM
Spencer David M.Chief Scientific OfficerJul 10Sale11.5410,000115,400138,965Jul 12 04:43 PM
Musso Alan ACFO and TreasurerMay 25Sale12.246,31177,25454,908May 26 03:07 PM
BAKER BROS. ADVISORS LP10% OwnerMar 24Buy12.00166,6661,999,9924,527,089Mar 28 05:05 PM
Slawin Kevin M.DirectorFeb 07Sale12.5430,000376,215294,982Feb 09 04:11 PM
Slawin Kevin M.Chief Technology OfficerDec 15Sale15.4530,000463,539324,982Dec 19 04:13 PM